Daniel Calkins
Known title: Chief Financial OfficerCIK: 0001951861
Associated companies
Transaction History
| VSTM | ▼ Sell | Open Market | 2,566 | $21K | 10/1/2026 | View on chart |
| VSTM | ▲ Buy | Grant | 8,333 | $0 | 9/30/2026 | View on chart |
| VSTM | ▼ Sell | Open Market | 55 | $424 | 9/21/2026 | View on chart |
| VSTM | ▼ Sell | Open Market | 57 | $235 | 6/22/2026 | View on chart |
| VSTM | ▼ Sell | Open Market | 4,032 | $17K | 6/22/2026 | View on chart |
| VSTM | ▲ Buy | Grant | 57 | $327 | 3/20/2026 | View on chart |
| VSTM | ▲ Buy | Grant | 16,665 | $0 | 1/21/2026 | View on chart |
| VSTM | ▼ Sell | Open Market | 5,039 | $36K | 1/12/2026 | View on chart |
| VSTM | ▼ Sell | Open Market | 80 | $629 | 12/24/2025 | View on chart |
| VSTM | ▼ Sell | Open Market | 25 | $231 | 9/24/2025 | View on chart |
| VSTM | ▼ Sell | Open Market | 57 | $518 | 9/22/2025 | View on chart |
| VSTM | ▼ Sell | Open Market | 25 | $118 | 6/23/2025 | View on chart |
| VSTM | ▼ Sell | Open Market | 4,110 | $21K | 6/20/2025 | View on chart |
| VSTM | ▼ Sell | Open Market | 11,143 | $91K | 5/20/2025 | View on chart |
| VSTM | ▲ Buy | Grant | 38,850 | $0 | 5/16/2025 | View on chart |
| VSTM | ▼ Sell | Open Market | 26 | $183 | 3/24/2025 | View on chart |
| VSTM | ▼ Sell | Open Market | 65 | $448 | 3/20/2025 | View on chart |
| VSTM | ▲ Buy | Grant | 38,800 | $0 | 1/10/2025 | View on chart |
| VSTM | ▼ Sell | Open Market | 6 | $42 | 1/6/2025 | View on chart |
| VSTM | ▼ Sell | Open Market | 28 | $109 | 12/24/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 65 | $282 | 12/20/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 6 | $17 | 10/7/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 28 | $75 | 9/24/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 65 | $182 | 9/20/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 7 | $18 | 7/9/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 28 | $88 | 6/24/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 67 | $212 | 6/20/2024 | View on chart |
| VSTM | ▲ Buy | Grant | 38,850 | $0 | 6/18/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 6 | $65 | 4/5/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 25 | $301 | 3/25/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 55 | $609 | 3/20/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 6 | $51 | 1/5/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 25 | $202 | 12/26/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 57 | $452 | 12/20/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 5 | $37 | 10/5/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 25 | $235 | 9/25/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 232 | $2K | 9/21/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 5 | $40 | 7/6/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 26 | $212 | 6/26/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 75 | $28 | 4/5/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 378 | $159 | 3/24/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 74 | $32 | 1/5/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 1,246 | $411 | 12/27/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Verastem presents ovarian cancer data at IGCS, outlines pipeline
Verastem Oncology reported a late‑breaking oral presentation of its RAMP 201 low‑grade serous ovarian cancer molecular profiling and tumor biomarker analysis at the IGCS 2026 Annual Global Meeting. The company also highlighted the launch of its ovarian cancer therapy and progress on the KRAS G12D program during an H.C. Wainwright event. These updates reflect ongoing clinical development and investor communication around its oncology pipeline.
Verastem presents ovarian cancer data at IGCS, outlines pipeline. Verastem Oncology reported a late‑breaking oral presentation of its RAMP 201 low‑grade serous ovarian cancer molecular profiling and tumor biomarker analysis at the IGCS 2026 Annual Global Meeting. The company also highlighted the launch of its ovarian cancer therapy and progress on the KRAS G12D program during an H.C. Wainwright event. These updates reflect ongoing clinical development and investor communication around its oncology pipeline.